Louse-borne relapsing fever (LBRF)
Also known as: Louse-borne relapsing fever
Methodology & AI Transparency ⓘ
Louse-borne relapsing fever (LBRF) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Louse-borne relapsing fever (LBRF) (also termed Louse-borne relapsing fever) (A68.0) in Infections & Antivirals relies on antimicrobial stewardship (narrow-spectrum in Louse-borne relapsing fever (LBRF) (A68.0: pathogen-directed duration) or), guiding step-wise therapeutic adjustments toward C-Reactive Protein / in Louse-borne relapsing fever (LBRF) (A68.0: Procalcitonin) (Resolution to baseline (A68.0)).
- 2 Real-world patient consensus: Clinical coding for Louse-borne relapsing fever (LBRF) uses ICD-10 A68.0 across Infections & Antivirals specialty care.
- 3 Typical cash cost range: Workup highlights for Louse-borne relapsing fever (LBRF) (A68.0): antimicrobial stewardship (narrow-spectrum in Louse-borne relapsing fever (LBRF) (A68.0: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Longitudinal Louse-borne relapsing fever (LBRF) monitoring tracks Complete Blood Count in Louse-borne relapsing fever (LBRF) (A68.0: (WBC & Differential)) toward WBC 4.0 – 10.0 x10^3/uL (A68.0).
Ask our AI Specialists anything about Louse-borne relapsing fever (LBRF)
What Is Louse-borne relapsing fever (LBRF)?
Clinical triage of Louse-borne relapsing fever (LBRF) (also termed Louse-borne relapsing fever) (A68.0) in Infections & Antivirals relies on antimicrobial stewardship (narrow-spectrum in Louse-borne relapsing fever (LBRF) (A68.0: pathogen-directed duration) or), guiding step-wise therapeutic adjustments toward C-Reactive Protein / in Louse-borne relapsing fever (LBRF) (A68.0: Procalcitonin) (Resolution to baseline (A68.0)).
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Louse-borne relapsing fever (LBRF) (A68.0) center on tissue neutrophil/lymphocyte recruitment [Louse-borne relapsing fever (LBRF) A68.0]. targeted infections & antivirals interventions aim to normalize Complete Blood Count in Louse-borne relapsing fever (LBRF) (A68.0: (WBC & Differential)).
Common Symptoms & Clinical Signs
- • Presentation of Louse-borne relapsing fever (LBRF) (A68.0): regional lymph node in Louse-borne relapsing fever (LBRF) (A68.0: tenderness or acute)
- • Secondary Louse-borne relapsing fever (LBRF) clinical sign: acute fever, chills, in Louse-borne relapsing fever (LBRF) (A68.0: malaise, and myalgias)
- • Symptom flares in Louse-borne relapsing fever (LBRF) correlating with Complete Blood Count in Louse-borne relapsing fever (LBRF) (A68.0: (WBC & Differential)) deviation outside WBC 4.0 – 10.0 x10^3/uL (A68.0)
- • Functional infections & antivirals impact requiring antimicrobial stewardship (narrow-spectrum in Louse-borne relapsing fever (LBRF) (A68.0: pathogen-directed duration) or) evaluation (A68.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Louse-borne relapsing fever (LBRF) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | A68.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Louse-borne relapsing fever (LBRF) (A68.0: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (A68.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Louse-borne relapsing fever (LBRF) (A68.0: Procalcitonin) | Resolution to baseline (A68.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Louse-borne relapsing fever (LBRF) (A68.0: Culture & Sensitivity) | Pathogen clearance / negative test (A68.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Louse-borne relapsing fever (LBRF)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Glatiramer Acetate Injection Glatiramer Acetate Injection Generic • RxCUI 1111641 | FDA Prescription Therapeutic Agent | 81% | $39.6680 | $ 185.00 /mo |
| Dimethyl Fumarate Tecfidera • RxCUI 1373483 | Multiple sclerosis Agent | 92% | $0.3817 | $ 9.05 /mo |
| Teriflunomide Aubagio • RxCUI 1310525 | Pyrimidine Synthesis Inhibitor | 94% | $0.2917 | $ 11.05 /mo |
| Interferon Beta-1a Avonex, Rebif Rebidose • RxCUI 727813 | Interferon beta | 78% | $8406.9391 | $ 185.00 /mo |
| Fingolimod Gilenya • RxCUI 1012895 | Sphingosine 1-phosphate Receptor Modulator | 76% | $1.4225 | $ 43.53 /mo |
| Cladribine Mavenclad • RxCUI 2122634 | Purine Antimetabolite | 92% | $2.4900 | $ 11362.63 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Louse-borne relapsing fever (LBRF))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Phase 3 study evaluating the safety and real-world benefits of oteseconazole in: What a 219-Participant Study Found In participants with recurrent vulvovaginal candidiasis, oteseconazole was safe and efficacious in the treatment and prevention of recurrent acute vulvovaginal candidiasis episodes and was noninferior to vulvovaginal... American journal of obstetrics and gynecology • 2022-12-15 • Phase III Randomized Trial | N = 219 | 88/100 | PMID 35863457 ↗ |
| Can This Approach Help? Inside the Latest Research on Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of Dolutegravir-based and darunavir-based regimens initiated during PHI strongly and similarly decreased the blood reservoir size. The Journal of antimicrobial chemotherapy • 2022-08-25 • Phase III Randomized Trial | N = 101 | 82/100 | PMID 35762503 ↗ |
Louse-borne relapsing fever (LBRF) Patient Community & “People Like Me” Threads
Filter Louse-borne relapsing fever (LBRF) community threads and patient logs by age, biological sex, dosage, and treatment duration.